Neuromyelitis Optica Spectrum Disorder Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 592.17 Million |
| Market Size (2029) | USD 804.22 Million |
| CAGR (2024 - 2029) | 6.31 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Neuromyelitis Optica Spectrum Disorder Market Analysis
The Neuromyelitis Optica Spectrum Disorder Market size is estimated at USD 592.17 million in 2024, and is expected to reach USD 804.22 million by 2029, growing at a CAGR of 6.31% during the forecast period (2024-2029).
The major factors driving the growth of the market for neuromyelitis optica spectrum disorder include the increasing incidence and prevalence of neuromyelitis optica spectrum disorder (NMOSD), rising demand for better treatment options, increasing research and development activities, and surging number of product approvals.
The rising prevalence of NMOSD worldwide is projected to drive the demand for immunosuppressive, monoclonal antibodies, and other drugs for its treatment, thereby driving market growth. For instance, according to an article published by the Neurological Sciences Journal in February 2023, the global prevalence and incidence rates of NMOSD ranged from 0.07 to 10 and 0.029 to 0.880 per 100,000 people, respectively.
According to an article published by StatPearls Journal in January 2024, NMOSD exhibited varying prevalence rates among demyelinating diseases worldwide. While it accounted for 1% to 2% in the United States and Italy, the figures soared to 13.7% in India and exceeded 30% in Thailand. As per the same source, NMOSD either relapsed, which occurs in 80% to 90% of cases, or was monophasic. The treatment often involves a brief stint of immunosuppressive therapy, commonly a corticosteroid, followed by a more prolonged regimen. Thus, the high prevalence of NMOSD and the high remission rate of the disease are projected to drive the demand for innovative drugs during the forecast period.
Various organizations are working toward providing funding support to researchers for the development of drugs to treat NMOSD. For instance, in July 2022, The Sumaira Foundation awarded research grants of up to USD 25,000 to nonprofit organizations, researchers, and institutions engaged in research into prevention, treatments, and a cure for NMOSD. Thus, such initiatives are likely to increase the research and development activities related to NMOSD, driving overall market growth.
Therefore, factors such as increasing incidence and prevalence of neuromyelitis optica spectrum disorder (NMOSD), rising demand for better treatment options, increasing research and development activities, and surging number of product approvals are projected to drive market growth. However, the high cost of therapy for NMOSD is projected to restrain market growth during the forecast period.
Neuromyelitis Optica Spectrum Disorder Market Trends
The Monoclonal Antibody Drugs Segment is Expected to Register a High CAGR During the Forecast Period
Monoclonal antibodies (mAbs) for treating NMOSD work by targeting specific immune system components to prevent attacks. Rituximab and inebilizumab target CD20 and CD19 on B cells, respectively, leading to their depletion and reducing the production of pathogenic autoantibodies. Eculizumab targets the complement protein C5, inhibiting the formation of the membrane attack complex, which reduces damage to the central nervous system. Satralizumab targets the interleukin-6 receptor, modulating the inflammatory response and reducing immune system overactivity. These targeted mechanisms help in controlling the autoimmune processes underlying NMOSD, thereby preventing relapses and improving patient outcomes.
The monoclonal antibody drugs segment is expected to dominate the market due to its high efficacy and tolerability in treating autoimmune diseases, including neuromyelitis optica spectrum disorder. For instance, according to an article published by Springer Journal in March 2023, monoclonal antibodies such as rituximab, ibalizumab, natalizumab, and eculizumab demonstrated high efficacy in reducing the frequency and severity of NMOSD attacks. These treatments target specific pathways involved in the disease's pathogenesis, providing more effective and tailored therapy than broad-spectrum immunosuppressants. As per the same source, clinical trials showed significant reductions in attack rates and improved quality of life for patients treated with these mAbs, thereby driving the demand for mAbs for NMOSD treatment.
The approval of multiple mAbs by regulatory bodies like the FDA enhanced the availability of these treatments, driving the segment鈥檚 growth. For instance, according to an article published by Elsevier in December 2022, the FDA approved inebilizumab, eculizumab, and satralizumab for NMOSD, which boosted their adoption in clinical practice.
Comparative studies highlighted the superior outcomes associated with mAbs, such as longer life expectancy and higher quality-adjusted life years, driving the adoption of these drugs worldwide. For instance, as per the study conducted by the Journal of Neurology in September 2023, the monoclonal anti-CD19 antibody inebilizumab, which, in addition to B cells, also targets CD19-expressing antibody-producing plasmablasts, was proven beneficial in AQP4-IgG-positive NMOSD. Thus, such evidence supports the preference for mAb treatments over traditional therapies, thereby driving the segment鈥檚 growth.
The rising number of drug approvals is also projected to drive segmental growth during the forecast period. For instance, in June 2022, Zenyaku Kogyo Co. Ltd and Chugai Pharmaceutical Co. Ltd received regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for an anti-CD20 monoclonal antibody Rituxan intravenous injection of 100 mg and 500 mg for the prevention of recurrence of neuromyelitis optica spectrum disorder in Japan.
Thus, the increasing efficacy and tolerability of monoclonal antibody drugs, rising product approvals, and research and development activities by market players are driving the growth of this segment, which is further expected to propel overall market growth over the forecast period.
North America is Anticipated to Hold a Significant Market Share During the Forecast Period
North America holds a significant share of the NMOSD market owing to factors such as the increasing incidence and prevalence of NMOSD. For instance, according to an article published by Sage Journals in January 2024, the age and sex-adjusted estimate of people with NMOSD in the United States was 15,413 females and 6,233 males in 2022.
The region's well-established healthcare infrastructure and availability of efficient treatment methods contribute to the market's growth. Moreover, non-profit organizations' financial assistance programs and increasing research and development activities in the region support the market's growth. For example, the Patient Access Network (PAN) Foundation launched a new financial assistance program in November 2023 to support individuals living with NMOSD.
Product approvals and increasing research and development activities in the region are driving the market's growth. For instance, in May 2022, Alexion reported positive results for the open-label Phase III CHAMPION-NMOSD trial of ULTOMIRIS (ravulizumab-cwvz). The study showed a positive impact on relapse in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) NMOSD compared to the external placebo arm from the pivotal SOLIRIS PREVENT clinical trial.
The increasing prevalence of NMOSD, rising research and development activities, and product approvals are expected to fuel the growth of the NMOSD treatment market in North America in the near future.
Neuromyelitis Optica Spectrum Disorder Industry Overview
The neuromyelitis optica spectrum disorder market is semi-consolidated, with many major players operating in it. Companies are focusing on adopting various business strategies such as collaborations, acquisitions, and product approvals to maintain their market position. Key players in this market include Hoffmann-La Roche Ltd, Horizon Therapeutics PLC, TG Therapeutics, Opexa Therapeutics, and Mitsubishi Tanabe Pharma.
Neuromyelitis Optica Spectrum Disorder Market Leaders
-
Hoffmann-La Roche Ltd
-
TG Therapeutics
-
Opexa Therapeutics
-
Mitsubishi Tanabe Pharma
-
Horizon Therapeutics plc (Viela Bio)
*Disclaimer: Major Players sorted in no particular order
Neuromyelitis Optica Spectrum Disorder Market News
- March 2024: Alexion Pharmaceuticals, a subsidiary of AstraZeneca, received US Food and Drug Administration (US FDA) approval for its ULTOMIRIS (ravulizumab-cwvz) drug. This drug is a long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).
- October 2023: Chugai Pharma Taiwan Ltd, a subsidiary of Chugai Pharmaceutical Co. Ltd, launched Enspryng drug for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult and adolescent patients over 12 years old who are anti-aquaporin-4 (AQP4) antibody positive as the first indication in Taiwan.
Neuromyelitis Optica Spectrum Disorder Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Neuromyelitis Optica Spectrum Disorder
4.2.2 Increasing Research and Development Activities, Product Approvals and Rising Demand for Better Treatment Options
4.3 Market Restraints
4.3.1 High Cost of Therapy for Neuromyelitis Optica Spectrum Disorder
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value-USD)
5.1 By Treatment
5.1.1 Monoclonal Antibody Drugs
5.1.2 Immunosuppressive Agents
5.1.3 Plasma Exchange Therapy
5.1.4 Other Treatments
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Rest of the World
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Hoffmann-La Roche Ltd
6.1.2 Horizon Therapeutics PLC (Viela Bio)
6.1.3 AstraZeneca
6.1.4 Mitsubishi Tanabe Pharma
6.1.5 Harbour BioMed
6.1.6 RemeGen
6.1.7 Teva Pharmaceutical Industries Ltd
6.1.8 Horizon Therapeutics PLC
6.1.9 TG Therapeutics
6.1.10 Opexa Therapeutics
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Neuromyelitis Optica Spectrum Disorder Industry Segmentation
As per the scope of the report, neuromyelitis optica spectrum disorder is an autoimmune disorder in which white blood cells and antibodies attack and damage the optic nerve, resulting in discomfort and visual loss, spinal cord causing paralysis, loss of sensation in the legs and arms, and problems with bladder and bowel function.
The market for neuromyelitis optica spectrum disorder is segmented by treatment and geography. By treatment, the market is segmented into immunosuppressive agents, plasma exchange therapy, and other treatments. By geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The report offers the value (USD) for all the above segments. The report also covers the estimated market sizes and trends for 13 countries across major regions globally.
| By Treatment | |
| Monoclonal Antibody Drugs | |
| Immunosuppressive Agents | |
| Plasma Exchange Therapy | |
| Other Treatments |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| Rest of the World |
Neuromyelitis Optica Spectrum Disorder Market Research FAQs
How big is the Neuromyelitis Optica Spectrum Disorder Market?
The Neuromyelitis Optica Spectrum Disorder Market size is expected to reach USD 592.17 million in 2024 and grow at a CAGR of 6.31% to reach USD 804.22 million by 2029.
What is the current Neuromyelitis Optica Spectrum Disorder Market size?
In 2024, the Neuromyelitis Optica Spectrum Disorder Market size is expected to reach USD 592.17 million.
Who are the key players in Neuromyelitis Optica Spectrum Disorder Market?
Hoffmann-La Roche Ltd, TG Therapeutics, Opexa Therapeutics, Mitsubishi Tanabe Pharma and Horizon Therapeutics plc (Viela Bio) are the major companies operating in the Neuromyelitis Optica Spectrum Disorder Market.
Which is the fastest growing region in Neuromyelitis Optica Spectrum Disorder Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Neuromyelitis Optica Spectrum Disorder Market?
In 2024, the North America accounts for the largest market share in Neuromyelitis Optica Spectrum Disorder Market.
What years does this Neuromyelitis Optica Spectrum Disorder Market cover, and what was the market size in 2023?
In 2023, the Neuromyelitis Optica Spectrum Disorder Market size was estimated at USD 554.80 million. The report covers the Neuromyelitis Optica Spectrum Disorder Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Neuromyelitis Optica Spectrum Disorder Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Neuromyelitis Optica Industry Report
Statistics for the 2023 Neuromyelitis Optica market share, size and revenue growth rate, created by 糖心vlog传媒鈩� Industry Reports. Neuromyelitis Optica analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
